A detailed history of Blair William & CO transactions in Revance Therapeutics, Inc. stock. As of the latest transaction made, Blair William & CO holds 85,998 shares of RVNC stock, worth $221,014. This represents 0.0% of its overall portfolio holdings.

Number of Shares
85,998
Previous 290,515 70.4%
Holding current value
$221,014
Previous $746,000 70.38%
% of portfolio
0.0%
Previous 0.0%

Shares

23 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

SELL
$2.57 - $2.57 $525,608 - $525,608
-204,517 Reduced 70.4%
85,998 $221,000
Q2 2024

Aug 12, 2024

SELL
$2.34 - $4.73 $90,679 - $183,296
-38,752 Reduced 11.77%
290,515 $746,000
Q1 2024

May 09, 2024

BUY
$4.65 - $9.31 $168,878 - $338,120
36,318 Added 12.4%
329,267 $1.62 Million
Q4 2023

Feb 12, 2024

SELL
$5.81 - $11.2 $193,804 - $373,598
-33,357 Reduced 10.22%
292,949 $2.58 Million
Q3 2023

Nov 09, 2023

SELL
$11.47 - $25.07 $1.95 Million - $4.26 Million
-169,969 Reduced 34.25%
326,306 $3.74 Million
Q2 2023

Aug 11, 2023

BUY
$24.7 - $37.61 $4.68 Million - $7.12 Million
189,398 Added 61.72%
496,275 $12.6 Million
Q1 2023

May 12, 2023

BUY
$18.36 - $35.27 $3.33 Million - $6.4 Million
181,372 Added 144.51%
306,877 $9.88 Million
Q4 2022

Feb 10, 2023

BUY
$18.32 - $30.66 $278,464 - $466,032
15,200 Added 13.78%
125,505 $2.32 Million
Q3 2022

Nov 09, 2022

BUY
$14.33 - $28.47 $1.38 Million - $2.74 Million
96,112 Added 677.18%
110,305 $2.98 Million
Q2 2022

Aug 10, 2022

BUY
$11.52 - $20.4 $17,763 - $31,456
1,542 Added 12.19%
14,193 $196,000
Q1 2022

May 13, 2022

SELL
$12.36 - $20.31 $3,708 - $6,093
-300 Reduced 2.32%
12,651 $247,000
Q4 2021

Feb 14, 2022

SELL
$12.46 - $27.87 $1.16 Million - $2.6 Million
-93,280 Reduced 87.81%
12,951 $211,000
Q3 2021

Nov 12, 2021

BUY
$25.78 - $33.21 $917,690 - $1.18 Million
35,597 Added 50.4%
106,231 $2.96 Million
Q2 2021

Aug 12, 2021

BUY
$26.8 - $31.84 $780,416 - $927,180
29,120 Added 70.15%
70,634 $2.09 Million
Q1 2021

May 13, 2021

BUY
$24.03 - $29.97 $505,422 - $630,359
21,033 Added 102.7%
41,514 $1.16 Million
Q4 2020

Feb 09, 2021

BUY
$23.41 - $28.34 $225,672 - $273,197
9,640 Added 88.92%
20,481 $580,000
Q3 2020

Nov 06, 2020

SELL
$23.23 - $34.3 $276,320 - $407,998
-11,895 Reduced 52.32%
10,841 $273,000
Q2 2020

Aug 12, 2020

BUY
$12.6 - $26.55 $50,853 - $107,155
4,036 Added 21.58%
22,736 $555,000
Q1 2020

May 11, 2020

BUY
$12.46 - $27.81 $40,495 - $90,382
3,250 Added 21.04%
18,700 $277,000
Q4 2019

Feb 13, 2020

BUY
$11.66 - $20.15 $180,147 - $311,317
15,450 New
15,450 $251,000
Q2 2018

Aug 13, 2018

SELL
$27.45 - $33.35 $226,462 - $275,137
-8,250 Closed
0 $0
Q1 2018

May 15, 2018

SELL
$29.15 - $37.4 $137,005 - $175,780
-4,700 Reduced 36.29%
8,250 $254,000
Q4 2017

Feb 14, 2018

BUY
$24.55 - $36.3 $317,922 - $470,084
12,950
12,950 $463,000

Others Institutions Holding RVNC

About Revance Therapeutics, Inc.


  • Ticker RVNC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 82,305,696
  • Market Cap $212M
  • Description
  • Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DaxibotulinumtoxinA for injection, which has completed phase III clinical trials fo...
More about RVNC
Track This Portfolio

Track Blair William & CO Portfolio

Follow Blair William & CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Blair William & CO, based on Form 13F filings with the SEC.

News

Stay updated on Blair William & CO with notifications on news.